Cargando…

Comparing the Efficacy and Safety of Apixaban Versus Warfarin in Morbidly Obese Patients

This study was conducted to evaluate the efficacy and safety of apixaban versus warfarin in morbidly obese patients. A total of 250 morbidly obese patients with a body mass index (BMI) higher than 40 kg/m(2) or a body weight higher than 120 kg who were on anticoagulation therapy with either apixaban...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alotaibi, Sultan N, Hasan, Hani, Metwali, Hend, Aseeri, Mohammed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Cardiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659312/ https://www.ncbi.nlm.nih.gov/pubmed/36407232 http://dx.doi.org/10.7759/cureus.30303

Ejemplares similares

Safety and Efficacy of Apixaban vs Warfarin in Patients With Stage 4 and 5 Chronic Kidney Disease: A Systematic Review
por: Fatima, Hameeda, et al.
Publicado: (2022)

Effectiveness and Safety of Apixaban vs. Warfarin in Venous Thromboembolism Patients with Obesity and Morbid Obesity
por: Cohen, Alexander, et al.
Publicado: (2021)

Safety and effectiveness of apixaban compared to warfarin in dialysis patients
por: Reed, Daniel, et al.
Publicado: (2018)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Apixaban-Induced Hepatotoxicity
por: Ansari, Umair, et al.
Publicado: (2022)

Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
por: Lip, Gregory Y. H., et al.
Publicado: (2016)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Apixaban-Induced Pseudo-Ludwig’s Angina
por: Figaro, Nicholas, et al.
Publicado: (2022)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Successful Treatment Using Apixaban in a Patient on Hemodialysis with Uremic Calciphylaxis
por: Alasmari, Moudi M, et al.
Publicado: (2022)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Efficacy and Safety of Direct Factor Xa Inhibitors Versus Warfarin in Prevention of Primary and Secondary Ischemic Strokes in Non-Valvular Atrial Fibrillation: A Literature Review
por: Emamy, Mina, et al.
Publicado: (2020)

Delayed Vesicular Urticarial Dermatosis Due to Apixaban
por: Garzon-Siatoya, Wendy T, et al.
Publicado: (2021)

Effectiveness and Safety of Apixaban versus Warfarin in Venous Thromboembolism Patients with Chronic Kidney Disease
por: Cohen, Alexander T., et al.
Publicado: (2021)

Clinically Ambiguous Hemorrhagic Cardiac Tamponade Associated with Apixaban
por: Aguilar-Gallardo, Jose S, et al.
Publicado: (2022)

Adrenal Hemorrhage in a Patient Anticoagulated with Apixaban with Antiphospholipid Syndrome
por: Sanford, Zachary, et al.
Publicado: (2019)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
por: Martinez, Brandon K., et al.
Publicado: (2018)

Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial
por: Halvorsen, Sigrun, et al.
Publicado: (2014)

Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial
por: Hu, Peter T., et al.
Publicado: (2017)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Hemorrhagic Pericardial Effusion From Apixaban Use: Case Report and Literature Review
por: Nasir, Syed Alishan, et al.
Publicado: (2022)

Erratum: Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice
por: Weycker, Derek, et al.
Publicado: (2018)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

A Case of Limb-Threatening Hematoma in a Patient Taking Citalopram and Apixaban Concurrently
por: Datta, Sorabh, et al.
Publicado: (2021)

Renal Vein Thrombosis Treated With Apixaban in a Patient With COVID-19: A Case Report
por: Kakhktsyan, Tigran, et al.
Publicado: (2023)

Effectiveness and Safety of Apixaban Versus Warfarin Among Older Patients with Venous Thromboembolism with Different Demographics and Socioeconomic Status
por: Cohen, Alexander T., et al.
Publicado: (2021)

The Role of Warfarin and Rivaroxaban in the Treatment of Cerebral Venous Thrombosis
por: Fayyaz, Muniba, et al.
Publicado: (2019)

Warfarin Dosing Requirement According to Body Mass Index
por: Alshammari, Abdullah, et al.
Publicado: (2020)

A case of apixaban-associated idiopathic interstitial pneumonia
por: Yun, Won-Sik, et al.
Publicado: (2022)

Comparison of the Warfarin Dosing and Outcomes in Hmong Versus East Asians Patients: Real-World Data From an Integrated Healthcare System
por: Sun, Boguang, et al.
Publicado: (2022)

Apixaban/heparin/warfarin: Treatment failure: case report
Publicado: (2021)

Dual Anticoagulation With Warfarin and Apixaban: A Case Report
por: Parker, Kristen, et al.
Publicado: (2022)

Evaluation of Apixaban safety and effectiveness in morbidly obese patients with atrial fibrillation: a retrospective cohort study
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

Comparison of the Efficacy and Safety of Apixaban and Warfarin in the Prevention of Stroke in Patients With Non-valvular Atrial Fibrillation: A Meta-Analysis
por: Memon, Rahat A, et al.
Publicado: (2022)

Systematic Review and Meta-Analysis: Can We Compare Direct Oral Anticoagulants to Warfarin in Patients With Atrial Fibrillation and Bio-Prosthetic Valves?
por: Adhikari, Govinda, et al.
Publicado: (2021)

Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial
por: Woller, Scott C., et al.
Publicado: (2022)

Apixaban or Rivaroxaban Versus Warfarin for Treatment of Submassive Pulmonary Embolism After Catheter-Directed Thrombolysis
por: Groetzinger, Lara M., et al.
Publicado: (2018)

Effectiveness and safety of apixaban vs warfarin among venous thromboembolism patients at high-risk of bleeding
por: Cohen, Alexander T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r70aii9fi7sk2k7j65rh1segkp